2014

Resverlogix Conference Call & Webcast Announcement

TSX Exchange Symbol: RVX

CALGARY, Feb. 6, 2014 /PRNewswire/ - Resverlogix Corp. (TSX:RVX) will be hosting a conference call and webcast on Thursday, February 13, 2014 at 11 am MDT / 1 pm ET. The call will update the market on current clinical and business structure options.

Details for the conference call and webcast are as follows:

Link to webcast: http://services.choruscall.ca/links/resverlogix140213.html

Dial in numbers:
Canada & USA Toll Free Dial In: 1-800-319-4610
Outside of Canada & USA call: +1-604-638-5340  

About Resverlogix

Resverlogix Corp. (TSX:RVX) is a clinical stage biotechnology company developing compounds involving ApoA-I production. RVX-208 is a first-in-class small molecule in development for the treatment of diseases such as atherosclerosis, Diabetes Mellitus and Alzheimer's disease. RVX-208 is the first BET bromodomain inhibitor in clinical trials. Resverlogix's common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com. We can be followed on our blog at http://www.resverlogix.com/blog and our IR App found on Apple products iTunes and Android users (Google Play).

Company Contacts:        
         
Donald J. McCaffrey   
President and CEO    
Resverlogix Corp.   
Phone: 403-254-9252   
Email: don@resverlogix.com  
      Kenneth Lebioda   
SVP Business & Corporate Development
Resverlogix Corp.
Phone: 403-254-9252
Email: ken@resverlogix.com

 

SOURCE Resverlogix Corp.



More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.